Maze Therapeutics, Inc. (MAZE) Institutional Ownership

Ownership Summary

According to SEC filings for the period ending September 2025, Maze Therapeutics, Inc. (NASDAQ:MAZE) is held by 92 institutional firms.

• The percentage of Maze Therapeutics owned by institutions changed from 88.7% in June 2025 to 98.0% in September 2025, marking a slight up trend.
• On a quarter-over-quarter basis, institutional holdings shifted by 10.85%, with a year-over-year an unavailable change in the count of filers.
• During the quarter, 62 institutions bought more Maze Therapeutics shares, 15 sold shares, and 15 of the 92 total investors held their position steady.
• The aggregate institutional position in Maze Therapeutics now stands at 42.97Mn shares as of September 2025, after investors increased their holdings (up by 4.21Mn shares quarter on quarter which is down N/A shares year over year).
• With 6.07Mn shares, TRV GP IV, LLC commands the largest institutional position in Maze Therapeutics as of September 30, 2025, equating to 13.85% of the company.
• Among the most significant buyers of Maze Therapeutics during September 2025 were VR Adviser, LLC (1.23Mn), VANGUARD GROUP INC (915.34K), MARSHALL WACE, LLP (758.10K), BlackRock, Inc. (701.31K), Logos Global Management LP (615.39K).
• Leading sellers of Maze Therapeutics stock in September 2025 included Foresite Capital Management IV, LLC (1.59Mn), Matrix Capital Management Company, LP (832.50K), JANUS HENDERSON GROUP PLC (649.39K), HARVARD MANAGEMENT CO INC (545.13K), Foresite Capital Management V, LLC (258.90K).
• The top 10 institutional holders of Maze Therapeutics for the quarter ending September 2025 included TRV GP IV, LLC (6.07Mn), Frazier Life Sciences Management, L.P. (4.57Mn), ARCH Venture Management, LLC (4.12Mn), Deep Track Capital, LP (3.95Mn), Alphabet Inc. (2.41Mn), a16z Capital Management, L.L.C. (1.70Mn), Matrix Capital Management Company, LP (1.65Mn), VANGUARD GROUP INC (1.33Mn), BlackRock, Inc. (1.32Mn), VR Adviser, LLC (1.23Mn).